Easton Pharmaceuticals, Inc. (EAPH)

[tardelli007]

EAPH WILL NOT BE UNDERVALUED FOR LONG. HERE ARE THE FACTS. EASTON HAS ALREADY DISCLOSED THAT THEY HAVE RECEIVED $400,000 IN PURCHASE ORDERS DURING THE LAST QUARTER. THAT WILL MOST CERTAINLY BE SHOWN IN TVE NEXT QUARTERLY STATEMENTS DUE IN 1 to 2 WEEKS.

EASTON HAS SPENT $800,000 IN CAPITAL TOWARDS ACQUIRING LISCENCES. THAT IS COLD HARD CASH AND NOT NEW SHARE ISSUANCES AS OF YET.

SECOND PRODUCT KAUNCH WITH MAJOR PHARMACEUTICAL COMPANY. THIRD PRODUCT LAUNCH IS READY TO BE SIGNED WITH HUGE MULTI-NATIONAL PHARMA COMPANY. EASTON DOING BUSINESS WITH BIG COMPANIES SHOWS THAT THEY HAVE CREDIBILITY AND REAL PRODUCTS.

IBLISS BEING RENEGOTIATED ON CERTAIN TERMS. BUT THE MAIN DELAY HAS BEEN A BEW ACQUISITION REGARDING CULTIVATION OF MEDICAL WHICH WILL SOON BE RECREATIONAL MARIJUANA IN CANADA. ONCE THAT IS ANNOUNCED EXOECT A $.20 CENT STOCK.

MY FRIENDS I PREDICT A BIG PAYDAY FOR ALL LING SHAREHOLDERS.